These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
118 related articles for article (PubMed ID: 386320)
1. Detection of antidonor antibody: advantages of fibroblast target cells. Halloran PF; Aprile M; Haddad G; Robinette M Proc Clin Dial Transplant Forum; 1978 Nov 18-20; 8():49-55. PubMed ID: 386320 [TBL] [Abstract][Full Text] [Related]
2. Donor-specific antibodies in renal allograft recipients. A reevaluation of the 51Cr-release assays comparing fibroblast and lymphoid target cells. Halloran PF; Aprile M; Haddad G; Cunningham K; Robinette MA Transplantation; 1984 Apr; 37(4):356-8. PubMed ID: 6369664 [TBL] [Abstract][Full Text] [Related]
3. Anti-donor immune responses in prediction of transplant rejection. Stiller CR; StC Sinclair NR; Abrahams S; McGirr D; Singh H; Howson WT; Ulan RA N Engl J Med; 1976 Apr; 294(18):978-82. PubMed ID: 130555 [TBL] [Abstract][Full Text] [Related]
4. Effect of alloantibodies on corneal allograft survival. Hegde S; Mellon JK; Hargrave SL; Niederkorn JY Invest Ophthalmol Vis Sci; 2002 Apr; 43(4):1012-8. PubMed ID: 11923241 [TBL] [Abstract][Full Text] [Related]
5. The correlation of kidney transplant survival with lymphocyte mediated cytotoxicity on B cell targets. Nathan P; Plessinger RT; First MR Proc Clin Dial Transplant Forum; 1978 Nov 18-20; 8():62-7. PubMed ID: 386322 [TBL] [Abstract][Full Text] [Related]
6. Alloantibodies and outcomes of deceased donor kidney allografts. Cinti P; Pretagostini R; Lai Q; Tamburro ML; Rossi M; Poli L; Berloco P Hum Immunol; 2009 Aug; 70(8):651-4. PubMed ID: 19527761 [TBL] [Abstract][Full Text] [Related]
7. Characterization of in vivo-activated allospecific T lymphocytes propagated from human renal allograft biopsies undergoing rejection. Mayer TG; Fuller AA; Fuller TC; Lazarovits AI; Boyle LA; Kurnick JT J Immunol; 1985 Jan; 134(1):258-64. PubMed ID: 3155462 [TBL] [Abstract][Full Text] [Related]
8. Adverse presensitization to renal transplants. Detection by utilization of a D locus antigen-defined lymphoblastoid cell panel as targets in antibody-dependent cell-mediated cytotoxicity assays. Suthanthiran M; Fotino M; Cheigh JS; Rubin AL; Novogrodsky A; Stenzel KH Transplantation; 1979 May; 27(5):333-7. PubMed ID: 373190 [TBL] [Abstract][Full Text] [Related]
9. Autoantibody against fibroblasts in renal transplant recipients: analysis by 51Cr-release assays. Aprile M; Halloran P; Haddad G; Robinette M Clin Exp Immunol; 1981 Dec; 46(3):565-74. PubMed ID: 7039893 [TBL] [Abstract][Full Text] [Related]
10. Assessment of whole blood for antibody-dependent cell-mediated cytotoxicity in kidney patients. Dupont E Proc Eur Dial Transplant Assoc; 1977; 14():321-7. PubMed ID: 341133 [TBL] [Abstract][Full Text] [Related]
12. Pretransplant assays of alloimmunity in predicting renal graft outcome. Gailiunas P; Person A; Suthanthiran M; Carpenter CB; Garovoy MR Proc Clin Dial Transplant Forum; 1977; 7():1-3. PubMed ID: 356029 [TBL] [Abstract][Full Text] [Related]
13. High levels of CMV-IE-1-specific memory T cells are associated with less alloimmunity and improved renal allograft function. Nickel P; Bold G; Presber F; Biti D; Babel N; Kreutzer S; Pratschke J; Schönemann C; Kern F; Volk HD; Reinke P Transpl Immunol; 2009 Mar; 20(4):238-42. PubMed ID: 19032982 [TBL] [Abstract][Full Text] [Related]
14. The significance of the anti-class I response. II. Clinical and pathologic features of renal transplants with anti-class I-like antibody. Halloran PF; Schlaut J; Solez K; Srinivasa NS Transplantation; 1992 Mar; 53(3):550-5. PubMed ID: 1549846 [TBL] [Abstract][Full Text] [Related]
16. Value of donor-specific antibody detection in first-graft renal transplant recipients with a negative complement-dependent cytotoxic crossmatch. Mahmoud KM; Ismail AM; Sheashaa HA; Gheith OA; Kamal MM; Ghoneim MA Exp Clin Transplant; 2009 Jun; 7(2):124-8. PubMed ID: 19715518 [TBL] [Abstract][Full Text] [Related]
17. In vitro cytotoxicity by human lymphocytes from individuals immunized against histocompatibility antigens. II. Relation to HL-A incompatibility between effector and target cells. Lundgren G; Möller E; Thorsby E Clin Exp Immunol; 1970 May; 6(5):671-80. PubMed ID: 4920602 [TBL] [Abstract][Full Text] [Related]
19. Loss of tolerance to a maternal kidney transplant is selective for HLA class II: evidence from trans-vivo DTH and alloantibody analysis. Burlingham WJ; Jankowska-Gan E; VanBuskirk A; Orosz CG; Lee JH; Kusaka S Hum Immunol; 2000 Dec; 61(12):1395-402. PubMed ID: 11163098 [TBL] [Abstract][Full Text] [Related]
20. Alloantibodies and the outcome of cadaver kidney allografts. Vasilescu ER; Ho EK; Colovai AI; Vlad G; Foca-Rodi A; Markowitz GS; D'Agati V; Hardy MA; Ratner LE; Suciu-Foca N Hum Immunol; 2006 Aug; 67(8):597-604. PubMed ID: 16916655 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]